1. Home
  2. KROS

as of 02-18-2026 9:51am EST

$16.51
$0.01
-0.06%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Founded: 2015 Country:
N/A
Employees: N/A City: LEXINGTON
Market Cap: 584.9M IPO Year: N/A
Target Price: $23.00 AVG Volume (30 days): 257.7K
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $9.12 - $22.55 Next Earning Date: 01-01-0001
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 6898.87% Revenue Growth (next year): -96.05%
P/E Ratio: 10.49 Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered KROS Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 15 hours ago

AI Recommendation

hold
Model Accuracy: 74.52%
74.52%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: